Regulatory MSD takes on Pfizer’s Prevnar with new Capvaxive approval PharmaphorumMSD has claimed new territory for pneumococcal vaccines after getting FDA approval for use of Capvaxive in vulnerable children aged two to 17.Infectious DiseaseRead full story pharminent June 18, 2026 (Last updated: June 21, 2026) Pharmaphorum MSD has claimed new territory for pneumococcal vaccines after getting FDA approval for use of Capvaxive in vulnerable children aged two to 17. Infectious Disease Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: New biotech cAMPfield emerges with $180M to reshape IBD treatmentNext: Moderna flu vaccine wins unanimous support from FDA panel Related Stories Regulatory Outlook Therapeutics Secures FDA Approval for LYTENAVA pharminent July 31, 2026 Regulatory Outlook finally claims FDA approval for AMD drug pharminent July 27, 2026 Regulatory Outlook Therapeutics wins FDA approval for Lytenava in wet AMD pharminent July 27, 2026
